Abstract
Background:
Cocaine use disorder (CUD) is characterized by the continued use of cocaine despite serious impacts on life. This study focused on understanding the perspective of individuals with current CUD, individuals in CUD remission, and their supporters regarding current therapies, future therapies, and views on clinical trials for CUD.
Methods:
The online bulletin board (OBB) is a qualitative tool where participants engage in an interactive discussion on a virtual forum. Following completion of a screening questionnaire to determine eligibility, individuals in CUD remission and their supporters logged in to the OBB and responded to questions posed by the moderator. Individuals with current CUD participated in a one-time virtual focus group.
Results:
All individuals with current CUD and 94% of those in CUD remission reported a diagnosis consistent with CUD or substance use disorder during screening. Individuals with current CUD and their supporters were recruited from the United States (US). Individuals in CUD remission were recruited from five countries, including the US. Individuals with current CUD reported hesitation about seeking treatment due to stigma, a lack of privacy, and being labeled as a drug seeker; barriers to therapy included time, cost, and a lack of privacy. Participants wanted a safe therapy to stop cravings and withdrawal symptoms. Seven clinical trial outcomes, including long-term abstinence and craving control, were suggested based on collected insights.
Conclusion:
This study can help inform the design of clinical trials and emphasize the need for effective, safe, and accessible therapies. Recruiting participants will require significant trust building.
1 Introduction
Cocaine is used by an estimated 20 million people globally, with an annual prevalence of use of 0.4% among those aged 15ā64 years (1). Some of these individuals will develop cocaine use disorder (CUD), which is characterized by meeting at least two Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria such as āhazardous useā, āsocial or interpersonal problems related to useā, and āneglected major roles due to useā (2). The 2016 Global Burden of Disease study estimated an age-standardized prevalence of 77.6 CUD cases per 100,ā000 people worldwide (3). Furthermore, an increase of 39.7% in CUD diagnoses was reported from 2010 to 2016 (4), and rates of overdoses, including cocaine overdoses, have recently increased exponentially (5, 6).
Although there are approved pharmacotherapies for opioid, tobacco, and alcohol use disorders, the treatment options are limited for CUD, with no approved pharmacotherapies in the United States (US) or Europe despite multiple clinical trials in the last several decades (4, 7, 8). Brain stimulation modalities such as deep brain stimulation (DBS) and repetitive transcranial magnetic stimulation (rTMS) are add-on therapies that have an acute effect on a personās craving for drugs and alcohol. These modalities are utilized when pharmacological interventions are not successful, but may not always be available in certain regions or considered cost effective (9). Even though psychosocial and behavioral interventions have demonstrated efficacy in CUD, there is no one superior treatment, resulting in the use of a range of therapies (10). These therapies include evidence-based approaches such as individual counseling, cognitive behavioral therapy (CBT), community reinforcement approach (CRA), and contingency management (CM) (8). These treatments often demonstrate clinical benefit, but long-term abstinence remains elusive for the majority of patients with CUD (7ā9, 11).
Clinical trials frequently consider abstinence from cocaine use as the criterion of therapy efficacy (12). However, abstinence can be a difficult outcome to achieve, and may not be the ultimate goal for some patients. Recently, the US Food and Drug Administration issued a status update declaring their interest in the use of novel, non-abstinence-based outcomes as part of product development, along with the development of new products that address a fuller range of symptoms of addiction, such as cravings (13ā15).
Clinical trial participation and the response of the participant to psychotherapy are interconnected. Relapse rates are high in substance use disorder (SUD) studies, and dropout is an important predictor of relapse (16). Approximately 30% of participants drop out of SUD trials, and studies targeting cocaine use are associated with higher dropout rates than those involving tobacco smoking and heroin use. Because of this high dropout rate in SUD trials, it is difficult to observe the beneficial effect of treatment.
Supporters (defined here as friends or family members involved in caring for a patient with CUD) also play an important role in the effective treatment of patients with CUD. However, owing to the social stigma associated with CUD, few supporters share their burdens and perspectives, or receive support from their community (17). Some studies have explored the burden of the supporters in taking care of loved ones with alcohol use disorder (18ā22) and with SUD (17, 22ā24), but, to date, no studies have provided the supportersā perspectives on CUD and treatment options for the individuals they care for and support.
The online bulletin board (OBB) method used in this study is a moderated, qualitative tool where participants engage in an interactive discussion in an open virtual forum (25). To date, studies using an OBB have provided valuable insights into different health conditions (25ā28). To better understand patient and supporter perspectives, the current study used both an OBB and a supplemental virtual focus group to try and determine (1) patient and supporter preferences on an ideal therapy for CUD (2), patient and supporter perspectives on the design and execution of future CUD clinical trials, and (3) clinical trial potential outcomes that are the most important and useful to patients with CUD.
2 Methodology
2.1 Study design and setting
This study was conducted over 2 weeks from February to March 2021 across the following groups: individuals in CUD remission (five OBBs in the US, United Kingdom, France, Spain, and Brazil with individuals who reported they had recovered from CUD); supporters (one OBB in the US with friends or family members of someone with CUD); and individuals with current CUD (one focus group in the US with individuals currently diagnosed with CUD). An external vendor specializing in market research methodologies partnered with BGM, DL, SM, and KW to lead all recruitment, screening, and moderating efforts for the OBB and focus group.
A mix of recruitment methods were used, including contacting participants on market research panels, social media advertising in relevant special interest groups, and referrals from volunteers at rehabilitation clinics. Interested participants would then complete a series of screening questions (18 to 22 questions) over a secure survey platform. They would then receive a follow-up phone call from a trained staff member to confirm their eligibility and schedule their time in the OBB or virtual focus group.
Individuals in CUD remission and their supporters were requested to log in to the OBB for a total of 60Ā min split across 8 days over a 2-week period and respond to the questions posed by a trained moderator that spoke in the participantās respective native language. Depending on the day of the OBB, participants were asked anywhere from a total of 5 to 13 questions (Supplementary Material 2: Screeners). Participants were encouraged to engage in anonymous discussions with other participants to exchange their views and experiences.
Individuals with current CUD were requested to join a virtual focus group once for a 90-min discussion that was conducted by a trained moderator who asked a series of 40 open-ended questions that explored the objectives in Section 2.3. The virtual focus group occurred on a confidential online platform (InterVu, FocusVision, USA) to ensure that participant names and/or locations were not displayed. All recordings of the focus group were destroyed after transcription.
For the purpose of simplicity, pharmacological treatments, 12-step programs, and other community mutual help groups were included within the definition of therapies, as many individuals with SUD engage in these programs as an integral part of their remission.
2.2 Participants
During screening, to qualify as an individual with current CUD, participants had to report the use of ācocaineā or ācrack cocaineā regularly, report a diagnosis consistent with CUD or SUD, or answer āyesā to at least five DSM-5 criteria questions about CUD to ensure the inclusion of patients with self-reported CUD to have moderate to severe CUD. Individuals in CUD remission must have said āyesā to regularly using ācocaineā or ācrack cocaineā in the past, reported a past history of substance useāincluding cocaine useāor must have said āyesā to at least five DSM-5 criteria questions to attempt to ensure the inclusion of moderate to severe CUD.
A supporter was defined as a friend or family member of someone who regularly used cocaine. A supporter was eligible to participate if they stated they were caring for or supporting someone currently using ācrack cocaineā or ācocaineā. They must have said āyesā to five or more DSM-5 criteria questions about their loved oneās current cocaine use or confirmed a past diagnosis of CUD or SUD.
2.3 CUD OBB and focus group study objectives
The study objectives were as follows:
a) Gather participantsā insights into current therapies.
b) Assess satisfaction levels with current therapies.
c) Identify barriers to accessing treatment.
d) Obtain participantsā insights into an ideal future therapy for CUD.
e) Obtain participantsā insights into the design of future clinical trials for CUD therapy.
2.4 Qualitative analysis of participant responses
The main output for the OBB and the virtual focus group was a transcript of the discussion. The OBB also generated some additional outputs, such as images and responses to closed questions (e.g., agreement with statements or polling) that were analyzed alongside the transcripts. The anonymized data underwent thematic analysis by trained staff. Transcripts were reviewed iteratively by several team members to identify and examine key themes and patterns within interviews, within and across markets and patient demographics.
Additional details on the methodology as well as screener, OBB, and focus group questions can be found in the Supplementary Material Sections 1-3.
3 Results
3.1 Participants
All individuals with current CUD (N = 5) and 94% of those in remission reported a diagnosis consistent with current or past CUD or SUD. The remaining 6% of those in remission reported cocaine use consistent with CUD by patient history and DSM-5 criteria. Individuals with current CUD and supporters participating in the study were aged 22ā49 years (n = 5) and 33ā53 years (n = 6), respectively. Those in CUD remission (N = 35) were aged 22ā65 years and were from Brazil (n = 7), France (n = 4), Spain (n = 6), US (n = 12), and UK (n = 6). Details of participant demographics are presented in TableĀ 1.
TableĀ 1
| Individuals with current CUD | |||||
|---|---|---|---|---|---|
| Country | US | ||||
| Age range | 22ā49 years | ||||
| Sex | Male, n = 5 | ||||
| Individuals in CUD remission | |||||
| Country | Brazil | France | Spain | UK | US |
| Age range | 30ā60 years | 23ā50 years | 30ā60 years | 30ā49 years | 22ā65 years |
| Sex | Female, n = 2 | Female, n = 2 | Female, n = 1 | Female, n = 4 | Female, n = 9 |
| Male, n = 5 | Male, n = 2 | Male, n = 5 | Male, n = 2 | Male, n = 3 | |
| Time in remission (range) | 1 yearā24 years | 2 monthsā10 years | 3 yearsā18 years | 1 monthā14 years | 35 daysā10 years |
| ā¢ā | ā¢ā | ā¢ā | ā¢ā | ā¢ā | |
| Supporters | |||||
| Country | US | ||||
| Age range | 33ā53 years | ||||
| Sex | Female, n = 6 | ||||
| Relationship with CUD participant | Aunt, cousin, sister, friend, spouse, parent | ||||
| Living with CUD participant | Yes, n = 5 | ||||
| CBT, cognitive behavioral therapy; CUD, cocaine use disorder; UK, United Kingdom; US, United States. | |||||
Demographics of individuals with current CUD, individuals in CUD remission, and supporters.
3.2 Insights from participants regarding current therapies and barriers to treatment
3.2.1 Individuals with current CUD
Individuals with current CUD reported moderate satisfaction with available therapies (average score of 4; scale of 1ā7, with 7 being the highest possible score). Residential rehabilitation and 12-step programs prompted some negative feedback, while counseling and CBT were preferred. These individuals felt that society considered them as āonce an addict, always an addict,ā and that admitting they had a problem to a peer support group was challenging. Off-label medications received mixed views, as there were concerns about dependence and having to go to a healthcare professional (HCP). Most considered seeking professional help but were distrustful of HCPs due to concerns about a lack of anonymity or of being judged negatively by the HCP. Those who had approached HCPs were worried about the interventions being documented permanently in their medical records and being perceived as drug seekers in the future. Having a good connection with an HCP was considered a crucial factor for remission (Supplementary Material 4; Table S1).
Lifestyle changes were appealing to individuals with current CUD who were not interested in receiving formal treatment.
This participant group listed several barriers to available therapies, such as the time and effort required, the cost, and skepticism about the effectiveness of therapy. For working professionals, a concern was the potential stigma of requesting medical leave for the treatment of CUD. A summary of current therapies and barriers can be found in TableĀ 2.
TableĀ 2
| Preferred therapies for individuals with current CUD | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Counseling | Lifestyle changes | Peer support | 12-step program | CBT | Individual/family therapy | Residential rehabilitation | Medication | Alternative medication | Mobile applications | Medical devices |
| High appeal | Low appeal | No appeal | Negative reaction | High appeal | No mention | Negative reaction | Mixed reaction | Low appeal | Low appeal | No mention |
| ā¢āProvides a level of accountability ā¢āLack of judgment ā¢āDirect feedback ā¢āThe biggest drawback is cost | ā¢āRelevant only to self-reliant users | NA | ā¢āāOnce an addict, always an addictā ā¢āSeen as an outdated method with religious links ā¢āCan introduce users to peers to then take drugs with | ā¢āA practical option that allows users to learn how to change their behavior ā¢āOne participant had tried this but with no long-term success ā¢āThe biggest drawback is cost | NA | ā¢āImmersive but not practical ā¢āExpensive ā¢āHas a logistical impact on employment ā¢āIsolated from triggers and as such does not mimic real life | ā¢āInterested in potential new options ā¢āConcerns around anonymity ā¢āWould have to speak to HCP to access ā¢āCould become addicted to medication | ā¢āInterest was shown by a few participants | ā¢āAppealed to those looking toward taking practical steps | NA |
| Preferred therapies by supporters | ||||||||||
| High appeal | No appeal | No appeal | No appeal | No appeal | No appeal | Supporters looking for total environment change | No appeal | Low appeal | No appeal | No appeal |
| Barriers to treatment for individuals with current CUD | ||||||||||
| Time | Stigma | Cost | Hard work | Skepticism | ||||||
| The time required for therapy is one of the biggest barriers, with respondents reluctant to try something that will take a chunk of time from their life | Respondents are keen to hide their addiction from employers and as such cannot take much time off, and are hesitant for anything to be on their medical records | Money is a huge barrier; many of the treatments mentioned by respondents are highlighted as costly and difficult to access | A number of therapies are thought of as āhard workā and can initially be off-putting for respondents, particularly those who do not think they have an addiction problem and believe they can quit on their own | Respondents are skeptical about therapies; many therapies are seen as an expensive waste of both time and money with poor success rates, and as such, not something they feel particularly enthused about | ||||||
Insights from individuals with current CUD and supporters regarding current therapies/community mutual help groups used by CUD patients.
CBT, cognitive behavioral therapy; CUD, cocaine use disorder; HCP, healthcare professional; NA, not applicable.
3.2.2 Individuals in CUD remission
Of those in CUD remission, 86% were satisfied with the available therapies for CUD (FiguresĀ 1A, B). Individuals in CUD remission thought that CUD was not taken as seriously as other addictions, such as alcohol or opioid use disorders, so there were fewer options available (Supplementary Material 4; Table S1).
FigureĀ 1
Overall, 77% of those in CUD remission tried counseling as a form of treatment, with all participants from Brazil and France attempting it. A majority of the participants highlighted the neutral, judgment-free, professional approach to listening and being provided with useful guidance as the reason for trying counseling. However, either the perceived high cost or lack of health insurance coverage was a barrier for accessing counseling.
The next most commonly tried approaches were lifestyle changes and 12-step programs with 69% and 62% of participants having tried them, respectively. These approaches were reported to have few cost-related barriers; however, participants believed that it was critically important that individuals had sufficient motivation to try these approaches. Peer support groups and 12-step programs were favored by older (aged >49 years) individuals in CUD remission.
The majority of participants considered engaging in CBT, and 48% actually tried it.
In the UK, CBT is available through the National Health Service and can also be free or compulsory if compelled by law enforcement. However, in other locations, participants reported that it may be more difficult to access or find CBT options.
Individual and/or family therapy was tried by 36% of those in CUD remission. Participants thought therapy could help them recover from CUD and address other factors that led to their CUD. Involving family in therapy was viewed as a chance to mend relationships and allows the participantās family to better understand them. However, participants did state that involving family can be uncomfortable.
For participants in the US, residential rehabilitation was widely known, but the quality of such residential facilities was thought to vary in quality and approach. Residential rehabilitation was favored by those aged <49 years but was also deemed expensive and there was a perceived risk of relapse upon returning to everyday life.
Alternative therapies for CUD, including yoga, reiki, and hypnosis, were not well-known. In addition, only 3% of participants tried medications. Available off-label medications were considered unsuitable due to perceived factors like dependency, side effects, or concerns about being labeled a drug seeker.
Mobile applications were considered convenient but also thought to be impersonal and boring to use. Medical devices were mostly unheard of, and those individuals who were aware of them thought they were expensive and ineffective.
Concerns over lack of confidentiality was another barrier that prevented users from seeking out different therapies. However, participants had fewer concerns about visiting HCPs for medical care compared with those with current CUD.
In summary, in France and Spain, all participants tried counseling, and this was also a common therapy option in Brazil. Medication was considered more frequently in France than elsewhere. On average, the therapies detailed above were used less frequently in the UK than in other countries. Twelve-step programs were most widely used in the US, had a lower uptake in Spain, and were common in Brazil along with mobile applications. Residential rehabilitation was considered an option by participants in the US, but cost was a barrier.
See Supplementary Material 4; Table S1 for a detailed summary of insights from individuals in CUD remission regarding current therapies and barriers.
3.2.3 Supporters
Residential rehabilitation was favored by supporters looking for a total environment change. However, residential rehabilitation was considered expensive with a perceived risk of relapse upon returning to everyday life (TableĀ 2). Counseling was considered meaningful. Social stigma and concerns over confidentiality were viewed as barriers that prevented their loved ones from seeking out the different therapies.
3.3 Insights from participants regarding future therapies
3.3.1 Individuals with current CUD
Individuals with current CUD, when prompted to describe an āidealā therapy, stated that they wanted a therapy that addressed cravings, withdrawal symptoms, and the ālowsā of cocaine use (low mood, anxiety, and paranoia caused by the effect of cocaine wearing off) without developing a new addiction (TableĀ 3). Access to these new therapies should be through HCPs but, again, users mentioned hesitancy about approaching HCPs.
TableĀ 3
| Individuals with current CUD | Individuals in CUD remission | Supporters |
|---|---|---|
| ⢠| ⢠| ⢠|
| Detailed insights | ||
ā¢āOral treatment preferred
| ā¢āHolistic treatment preferred
| ā¢āQuick and convenient treatment preferred (preferably oral)
ā¢āIntensive treatment with ongoing support
ā¢āPractical support on issues such as housing, transport, jobs, money management and monitoring (to discourage relapse), nutrition, and sleep hygiene |
| ā¢āPotential for new mobile applications, CBT, peer support, etc. | ā¢āOral treatment
| ā¢āOral treatment
|
ā¢āRealistic tools focused on the following should be used by HCPs
| ā¢āNew treatment would be considered effective if the individual seemed like their old self again | |
ā¢āEffective treatment would mean:
| ||
Insights from participants regarding future therapies, including an ideal tool to measure treatment efficacy.
CBT, cognitive behavioral therapy; CUD, cocaine use disorder; HCP, healthcare professional.
3.3.2 Individuals in CUD remission
Individuals in CUD remission had similar views on future therapies to those with current CUD, including the importance of new therapies stopping or reducing cravings (72% of participants) and withdrawal symptoms (64% of participants) (TableĀ 3; FigureĀ 2). Individuals in CUD remission were more interested in holistic treatment options that were tailored to individual needs. They felt that if a pharmacological treatment existed, it should exist alongside a support system that would promote physical and mental health, improve oneās quality of life (QoL), and everyday relationships. To determine how individuals are doing on a new therapy, they recommended realistic HCP tools that combined clinical interviews and questionnaires with parameters such as assessment on physical appearance, patient logs on moods and cravings, and verifications with family and other professionals in contact with the patient.
FigureĀ 2
3.3.3 Supporters
Supporters wanted therapies, especially pharmacological therapies, that would stop or reduce cravings (33% of participants) and withdrawal symptoms (67% of participants). They also wanted long-term intensive therapies that were holistic and affordable, and included mental support for users and care for supporters (TableĀ 3; FigureĀ 2). They also noted that these therapies should be convenient and quick to ensure compliance and long-term abstinence (FigureĀ 2), with an emphasis on therapies that can improve QoL. Location, treatment flexibility, and willingness to undergo treatment were the barriers cited by the supporters. The cost of therapy was a potential barrier for supporters, if not reimbursable or covered by insurance (Supplementary Material 5; Table S2). Lastly, all participants had mixed views on pharmacological therapies due to concerns about safety, dependence, and an overall concern with pharmacological therapies being āeasy fixesā that would cater more to the symptoms than the root causes of their CUD. In their opinion, this could lead to relapse.
3.4 Insights from participants regarding future clinical trials on CUD
Most participants across the three groups were interested in clinical trials (TableĀ 4), but expressed some specific concerns, as outlined below.
TableĀ 4
| Individuals with current CUD | Individuals in CUD remission | Supporters | ||||||
|---|---|---|---|---|---|---|---|---|
| Benefits | Barriers | Suggestions | Benefits | Barriers | Suggestions | Benefits | Barriers | Suggestions |
| ā¢āAnonymity provided in clinical trials ā¢āPotential āfreeā access to an innovative treatment that works ā¢āHelping others and scientific advancement ā¢āWant to see CUD being taken more seriously ā¢āSome think they might be paid to participate ā¢āParticipants would be interested in learning more about clinical trials | ā¢āWould want to know the side effects of the medications required to be taken in the trial ā¢āConfidentiality very frequently mentionedāwould like to be registered by number and not by name ā¢āNot comfortable taking treatment on camera ā¢āVisiting the trial center in person would be more straightforward/confidential | ā¢āGuarantee of anonymity ā¢āThe doctor should check: āāIf the patient is still using cocaine āāIf the patient has used cocaine that day āāIf the patient has stopped using but used a few days prior āāHow long the patient has been using the drug āāLevels of drugs in the patientās system | ā¢āHelping others ā¢āand scientific advancement; some expressed particular interest in brain function; what works for different people; combination therapies ā¢āWant to see cocaine misuse being taken more seriously ā¢āCould help with additional tools to āstay soberā ā¢āSome think they might be paid to participate | ā¢āSome feel they would not be eligible as they no longer use cocaine ā¢āConcerns that taking part could be a trigger for use/relapse ā¢āSome were against medication in general ā¢āConcerns about side effects ā¢āConcerns about the hassle factor, e.g., duration ā¢āNo real personal benefits perceived ā¢āConcerns about anonymity, and having to explain to others what they are doing ā¢āNot comfortable being filmed as part of the trial ā¢āDisappointment if they receive a placebo ā¢āDislike of pharmaceutical companies | ā¢āGuarantee of anonymity ā¢āClear explanation of purpose and process; consent should be obtained ā¢āEmpathetic HCPs who treat trial participants with respect ā¢āNo stigma attached to participation ā¢āTransparency of results ā¢āProvision of psychological support ā¢āPleasant, relaxing environment with drinks and snacks (if visiting a clinic) ā¢āIdeally a payment or compensation provided to participants | ā¢āSave lives of people with CUD ā¢āHope that after multiple failed attempts, finally a treatment that might work ā¢āGreater understanding of addiction, and how it affects those with CUD ā¢āDevelopment of effective medications and treatment plans ā¢āThe individual will get intensive physical and psychological monitoring and treatment, which they may not be able to access otherwise | ā¢āConcerns that participation could be a trigger for use/relapse in the patient ā¢āUnsure about their loved oneās willingness to participate (privacy issues and/or reluctance in stopping cocaine use) ā¢āSome were against medication in general ā¢āConcerns about side effects ā¢āConcerns about the hassle factor, particularly the duration of therapy ā¢āConcern about anonymity; would need reassurance on confidentiality ā¢āConcern the patient may be uncomfortable with taking treatment on camera due to the anxiety, stigma, and fears around privacy ā¢āConcern about monitoring triggering āparanoiaā in the patient ā¢āDisappointment if the patient were to receive a placebo ā¢āComorbidities ā¢āDislike of pharmaceutical companies | ā¢āGuarantee of anonymity ā¢āTake time to explain trial process and monitoring carefully ā¢āEnsure the same trial personnel see the patient each time ā¢āEnsure the patient is not locked up or does not feel trapped ā¢āPleasant, relaxing environment with drinks and snacks (if visiting a clinic) |
Insights from participants regarding potential clinical trials on CUD.
CUD, cocaine use disorder; HCP, healthcare professional.
3.4.1 Individuals with current CUD
Access to free trial medication, an eagerness to advance scientific research on CUD, and assured anonymity were key motivators to participate in a clinical trial (TableĀ 4). Clinical trials were perceived as an opportunity for CUD to be taken more seriously in the medical and scientific fields. However, concerns about the potential side effects of medication and their privacy while being in a clinical trial were cited. Specifically, when prompted about their thoughts on taking medication via a video recording for compliance purposes, most participants were not supportive of this approach as it was considered intrusive. Although privacy was a concern, participants noted that anonymity in a clinical trial could also be a good motivator as they could take a potential trial treatment for their CUD without it being documented in their medical records.
3.4.2 Individuals in CUD remission
Individuals in remission had overall positive perceptions about participating in clinical trials but were concerned about their privacy and a lack of confidentiality (TableĀ 4). They were also worried about receiving placebo instead of an active treatment. Participants from the US were most interested in clinical trial participation, with 42% of participants showing definite interest and 42% of participants showing possible interest (FigureĀ 3).
FigureĀ 3
3.4.3 Supporters
Supporters thought that clinical trials could save lives and provide hope to loved ones who had multiple relapses (TableĀ 4). However, they were skeptical about the willingness of their friends and relatives to participate in these trials due to their loved oneās potential lack of interest in stopping their cocaine use or concerns over confidentiality and privacy. Similar to those with current CUD, supporters were also uncomfortable about their loved ones taking treatment on camera.
Based on the insights collected regarding current and future therapies as well as regarding potential clinical trials, seven outcomes were suggested by participants for the success of a therapy. To achieve long-term abstinence, a blood/urine test was run in only individuals in CUD remission. To stop or reduce cravings, a patient log was maintained, and a clinical interview was conducted in individuals with current CUD and individuals in CUD remission. To feel free from dependency, a patient log was maintained, a clinical interview was conducted, and verifying with other professionals or supporters was done in individuals in CUD remission as well. To improve physical health/prevent long-term problems, a full physical exam and clinical tests were performed in individuals in CUD remission. To improve mental health, an interview with a trusted, empathetic person/read non-verbal signs was conducted in individuals with current CUD, individuals in CUD remission, and supporters. To improve QoL, including with work and relationships, an interview with a trusted, empathetic person/read non-verbal signs was conducted in individuals in CUD remission. To achieve all of the above, a realistic tool that combines clinical interviews and questionnaires with other parameters such as physical appearance, patient logs on moods and cravings, and verifications with family and other professionals in contact with the patient were performed in individuals in CUD remission.
4 Discussion
Studies on substance use and SUD have found individual counseling, CBT, and 12-step programs, among others, to be effective interventions (29ā31). In the present study, counseling was the most popular therapy. Where it was available, CBT was popular among those looking for practical techniques to support their remission. Peer support groups and 12-step programs were of interest to older individuals in CUD remission (aged >49 years). Those with current CUD and some in remission found it challenging to connect with peers in a group setting and subsequently rejected the 12-step programs as outdated and religious in nature. Those with current CUD thought medication for comorbidities could be useful, but going to an HCP generated concerns about privacy, anonymity, stigma, and documented treatment. Both current and recovered individuals with CUD were concerned about off-label medications leading to dependence, or about being perceived or labeled as drug seekers. Residential rehabilitation was not frequently tried due to the high cost. Alternative medicine was not well-known as a CUD therapy. Medical devices and mobile applications were the least-used approaches for CUD therapy.
Costs of therapy, lack of anonymity, and social stigma were the frequently cited barriers to treatment for all groups of participants in this study, similar to other studies (32). The time required for therapy was a major barrier for those with current CUD, whereas location and flexibility of therapy were a concern for the supporters.
In the present study, those with current CUD were most interested in new therapies, and those in remission and supporters were more focused on other aspects such as psychosocial therapies. Although supporters were looking forward to fast-acting, effective oral therapies, those with current CUD or in remission were fearful about dependence or quick fixes where the root cause remained unaddressed. However, a common point of agreement among all participants was that a new therapy could stop or reduce cravings and withdrawal symptoms, and achieve longāterm abstinence.
Despite the potential drawbacks identified for clinical trials, such as intrusivity of being filmed if that was part of the clinical trial compliance measures, the interventions and questions in clinical trials as a possible trigger for relapse and paranoia, side effects, and concerns over receiving a placebo, there was a general interest and desire to contribute to science. The anonymity and privacy afforded by a clinical trial setting were also viewed favorably.
Limitations of the study included a modest study sample. Owing to the limitations of the format of the focus group, some questions varied between the OBB and the focus group. Because of cultural differences toward addiction and the willingness to talk about it, individuals with current CUD and their supporters were only from the US, which may have led to bias in the results. Consistent with qualitative research, the patient population was not balanced as in a standard clinical trial. Moreover, some participants (6% of the individuals in CUD remission) had no diagnosis consistent with CUD, although they did have at least five criteria of SUD per DSM-5 criteria.
5 Conclusion
Experiences with therapy varied among participants, and several attempts were often needed to stop or reduce cocaine use. Satisfaction with the available treatment options was low, with concerns about efficacy, therapies not being tailored to cocaine use, and cost to the patient. A holistic treatmentāthat is, pharmacological treatment with personalized therapy that helps reduce cravings and is affordableāwas considered as ideal. Interest in a potential new oral treatment was mixed, with some concerns around dependence or misuse. Patient information and support tailored to stopping cocaine use would be beneficial, particularly if it is adaptable to the unique psychosocial needs of the individuals with current CUD or in CUD remission.
Long-term abstinence may be the main goal for a clinical trial; however, based on the perspectives of individuals with current or past CUD and supporters, other outcomes such as reduced cravings, improvement in physical and mental health, improvement in QoL, and prevention of long-term problems were also viewed as important considerations for potential clinical trials. Therapy outcomes need to include patient-led evaluation and objectives to realistically assess if the patient is still using cocaine.
Enthusiasm about clinical trials was high among the participants due to the anticipation of improved treatment options specific to CUD. However, those with current CUD reported many barriers to participation, particularly paranoia, which could be worsened if the trial required treatment compliance to be documented by video recording. This study suggests that participants require efforts to be made on building trust and ensuring the privacy of their personal information. Furthermore, although many legal and ethical safeguards exist to ensure anonymity and privacy of a clinical trial participantās data, this study made it clear that special care must be taken to explain to participants in CUD trials about their privacy rights and provide additional plain language educational materials regarding their privacy rights outside of the informed consent form. Participants had many concerns about their privacy and documentation of a potential CUD prescription drug in their medical record. As medical record privacy is a major barrier to individuals seeking professional help, it is important to identify ways to create an environment of assured privacy and anonymity once a medication is available on the market (e.g., coding the medication in the record).
With a growing interest in patient-informed clinical trial designs, this study highlights the unmet needs of individuals with current, or in remission from, CUD and their supporters. There is an urgent need to continue investing in research for new CUD therapies, given the scope of the problem and the soaring rates of cocaine use globally.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics statement
This study was conducted in accordance with EphMRA guidelines which state that ethics committee approval is not required if study met the criteria of market research. Therefore, Institutional Review Board approval was not sought for this market research study. All procedures involving human participants were performed in accordance with the declaration of Helsinki and guidelines for Good Epidemiology Practice. Standard procedures were adhered to for the protection of participantsā rights, including written informed consent, data privacy, anonymity, and the right to withdrawal, as well as thorough assessment of the qualifications of the vendor was undertaken. The participants provided their written informed consent to participate in this study.
Author contributions
SM: Conceptualization, methodology, visualization, project administration, funding acquisition; writing the original draft, reviewing and editing the subsequent drafts. DL: Conceptualization and writing the original draft; visualization, supervision, funding and acquisition; reviewing and editing the subsequent drafts. BG-M: Conceptualization, methodology, visualization, supervision, funding and acquisition; reviewing and editing the subsequent drafts. BK: Visualization and writing the original draft; reviewing and editing the subsequent drafts. VSM: Formal analysis and data curation. PB: Conceptualization, methodology, writing the original draft; reviewing and editing the subsequent drafts. SD: Writing the original draft and reviewing and editing the subsequent drafts. KW: Conceptualization, methodology, validation, visualization, project administration; writing the original draft; reviewing and editing the subsequent drafts. All authors contributed to the article and approved the submitted version.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study received funding from Novartis Institutes for BioMedical Research and Novartis Pharmaceutical Corporation (Global Health Development Unit, GDD), Basel, Switzerland.
Acknowledgments
The authors thank all of the participants of this study. They are also thankful to Adelphi Research, an independent market research agency, for conducting the OBB and the focus group, and compiling the data. The authors thank Shyamashree Dasgupta and Praful Narayan Kamble (NBS CONEXTS, Novartis Healthcare Pvt. Ltd.) for assistance in writing the manuscript, formatting, referencing, preparing tables and figures, incorporating the authorsā revisions.
Conflict of interest
BG-M was employed by Novartis Pharma AG at the time of this study. He is now employed by McGill University. DL, KW, SD, PB, VSM, and SM are employed by Novartis. BK is a paid consultant to CBT4CBT, LLC, which provides a digital CBT program to qualified clinical providers and organizations on a commercial basis. This conflict is managed by Yale University.
The authors declare that this study received funding from Novartis Institutes for BioMedical Research and Novartis Pharmaceutical Corporation (Global Health Development Unit, GDD). The funder had the following involvement with the study: collection, analysis, and interpretation of data, and in the decision to submit the article for publication.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1230699/full#supplementary-material
References
1
UNODC. World Drug Report 2021, Booklet 4 - Drug market trends: Cocaine, Amphetamine-type stimulants. Vienna, Austria: United Nations Publication (2021). Available at: https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_4.pdf
2
HasinDSO'BrienCPAuriacombeMBorgesGBucholzKBudneyAet al. Dsm-5 criteria for substance use disorders: Recommendations and rationale. Am J Psychiatry. (2013) 170:834ā51. doi:Ā 10.1176/appi.ajp.2013.12060782
3
AlcoholGBDDrug UseC. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet Psychiatry. (2018) 5:987ā1012. doi:Ā 10.1016/S2215-0366(18)30337-7
4
BrandtLChaoTComerSDLevinFR. Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer? Addiction. (2021) 116:694ā710. doi:Ā 10.1111/add.15242
5
HedegaardHMininoAMWarnerM. Drug overdose deaths in the United States, 1999-2018. NCHS Data Brief. (2020) 356):1ā8.
6
McCall JonesCBaldwinGTComptonWM. Recent increases in cocaine-related overdose deaths and the role of opioids. Am J Public Health. (2017) 107:430ā2. doi:Ā 10.2105/AJPH.2016.303627
7
BentzleyBSHanSSNeunerSHumphreysKKampmanKMHalpernCH. Comparison of treatments for cocaine use disorder among adults: A systematic review and meta-analysis. JAMA Netw Open. (2021) 4:e218049. doi:Ā 10.1001/jamanetworkopen.2021.8049
8
KampmanKM. The treatment of cocaine use disorder. Sci Adv. (2019) 5:eaax1532. doi:Ā 10.1126/sciadv.aax1532
9
SallingMMartinezD. Brain stimulation in ddiction. Neuropsychopharmacol. (2016) 41:2798ā809. doi:Ā 10.1038/npp.2016.80
10
DutraLStathopoulouGBasdenSLLeyroTMPowersMBOttoMW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. (2008) 165:179ā87. doi:Ā 10.1176/appi.ajp.2007.06111851
11
PenberthyJKAit-DaoudNVaughanMFanningT. Review of treatment for cocaine dependence. Curr Drug Abuse Rev. (2010) 3:49ā62. doi:Ā 10.2174/1874473711003010049
12
CzotyPWStoopsWWRushCR. Evaluation of the "Pipeline" for development of medications for cocaine use disorder: A review of translational preclinical, human laboratory, and clinical trial research. Pharmacol Rev. (2016) 68:533ā62. doi:Ā 10.1124/pr.115.011668
13
USFDA. Opioid Use Disorder: Endpoints for demonstrating effectiveness of drugs for treatment guidance for industry. (2020). Available at: https://https://www.fda.gov/media/114948/download
14
GottliebS. Remarks from Fda Commissioner Scott Gottlieb, M.D., as Prepared for Oral Testimony before the House Committee on Energy and Commerce Hearing, āFederal Efforts to Combat the Opioid Crisis: A Status Update on Cara and Other Initiatives. Administration USFD (2017). Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm582031.htm
15
KilukBDCarrollKMDuhigAFalkDEKampmanKLaiet al. Measures of outcome for stimulant trials: Acttion recommendations and research agenda. Drug Alcohol Depend. (2016) 158:1ā7. doi:Ā 10.1016/j.drugalcdep.2015.11.004
16
LappanSNBrownAWHendricksPS. Dropout rates of in-person psychosocial substance use disorder treatments: A systematic review and meta-analysis. Addiction. (2020) 115:201ā17. doi:Ā 10.1111/add.14793
17
UluyolFMBademliK. Feelings, thoughts and experiences of caregivers of individuals with substance use disorder. ADDICTA: Turkish J Addict. (2020) 7:199ā205. doi:Ā 10.5152/addicta.2020.20055
18
VaishnaviRKarthikMSBalakrishnanRSathianathanR. Caregiver burden in alcohol dependence syndrome. J Addict. (2017) 2017:8934712. doi:Ā 10.1155/2017/8934712
19
SwaroopacharyRKalasapatiLIvaturiSReddyC. Caregiver burden in alcohol dependence syndrome in relation to the severity of dependence. Arch Ment Health. (2018) 19:19ā23. doi:Ā 10.4103/amh.Amh_6_18
20
ShekhawatBSJainSSolankiHK. Caregiver burden on wives of substance-dependent husbands and its correlates at a tertiary care centre in Northern India. Indian J Public Health. (2017) 61:274ā7. doi:Ā 10.4103/ijph.IJPH_396_16
21
RospendaKMMinichLMMilnerLARichmanJA. Caregiver burden and alcohol use in a community sample. J Addict Dis. (2010) 29:314ā24. doi:Ā 10.1080/10550887.2010.489450
22
KadamKUnnithanVManeMAnganeA. Brewing caregiver burden: Indian insights into alcohol use disorder. Indian J Soc Psychiatry. (2020) 36:236ā42. doi:Ā 10.4103/ijsp.ijsp_117_19
23
MainaGOgenchukMPhaneufTKwameA. "I can't live like that": The experience of caregiver stress of caring for a relative with substance use disorder. Subst Abuse Treat Prev Policy. (2021) 16:11. doi:Ā 10.1186/s13011-021-00344-3.25
24
MannelliP. The burden of caring: Drug users & Their families. Indian J Med Res. (2013) 137:636ā8.
25
CookNSNagarSHJainABalpMMMaylanderMWeissOet al. Understanding patient preferences and unmet needs in non-alcoholic steatohepatitis (Nash): Insights from a qualitative online bulletin board study. Adv Ther. (2019) 36:478ā91. doi:Ā 10.1007/s12325-018-0856-0
26
PatalanoFGutzwillerFSShahBKumariCCookNS. Gathering structured patient insight to drive the pro strategy in copd: Patient-centric drug development from theory to practice. Adv Ther. (2020) 37:17ā26. doi:Ā 10.1007/s12325-019-01134-x
27
GriffithsKMReynoldsJVassalloS. An online, moderated peer-to-peer support bulletin board for depression: User-perceived advantages and disadvantages. JMIR Ment Health. (2015) 2:e14. doi:Ā 10.2196/mental.4266
28
CookNSTripathiPWeissOWaldaSGeorgeATBushellA. Patient needs, perceptions, and attitudinal drivers associated with obesity: A qualitative online bulletin board study. Adv Ther. (2019) 36:842ā57. doi:Ā 10.1007/s12325-019-00900-1
29
MagillMRayLKilukBHoadleyABernsteinMToniganJSet al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. J Consult Clin Psychol. (2019) 87:1093ā105. doi:Ā 10.1037/ccp0000447
30
BĆøgMFilgesTBrƤnnstrƶmLJĆørgensenA-MKFredrikkssonMK. 12-step programs for reducing illicit drug use. Campbell Systematic Rev. (2017) 13:1ā149. doi:Ā 10.4073/csr.2017.2
31
McGovernMPLambert-HarrisCAltermanAIXieHMeierA. A randomized controlled trial comparing integrated cognitive behavioral therapy versus individual addiction counseling for co-occurring substance use and posttraumatic stress disorders. J Dual Diagn. (2011) 7:207ā27. doi:Ā 10.1080/15504263.2011.620425
32
Center for Behavioral Health Statistics and Quality. 2015 National Survey on Drug Use and Health: Detailed Tables. Rockville, Md: Substance Abuse and Mental Health Services Administration (2016).
Summary
Keywords
cocaine use disorder, online bulletin board, individuals with current cocaine use disorder, individuals in cocaine use disorder remission, unmet needs, clinical trial outcomes
Citation
Maahs S, Leclair D, Gomez-Mancilla B, Kiluk BD, Muthusamy VS, Banerjee PS, Dasgupta S and Waye KM (2024) Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder. Front. Psychiatry 15:1230699. doi: 10.3389/fpsyt.2024.1230699
Received
29 May 2023
Accepted
30 January 2024
Published
29 February 2024
Volume
15 - 2024
Edited by
Dasiel Oscar Borroto-Escuela, Karolinska Institutet (KI), Sweden
Reviewed by
Sean Regnier, University of Kentucky, United States
Luis Miguel MartĆnez, University of La Frontera, Chile
Updates
Copyright
Ā© 2024 Maahs, Leclair, Gomez-Mancilla, Kiluk, Muthusamy, Banerjee, Dasgupta and Waye.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Denise Leclair, denise.leclair@novartis.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.